Dedication. Purpose. Table of Contents. Introduction. What is Nanomedicine?. What is Translational Medicine?. What is Innovation?. What is Intellectual Property?. From IP to IPO. What is Impact?. From Atoms to Proteins. Atoms and Molecules. Atoms of Life. Molecules of Life. Proteins. Genetics and DNA Sequencing. DNA and the Genetic Code. From DNA to Proteins and Cells. History of Genetics. Molecular Basis of Genetics. DNA Sequencing and the Human Genome Project. Sequencing Technologies. Chemical Sequencing. Sanger Sequencing, NGS and the $1,000 Genome Challenge. Second Generation DNA Sequencing. Third Generation DNA Sequencing. Fourth Generation DNA Sequencing. Sequencing Data Analysis. Bioethics. Business Aspects of Sequencing Technology and the Human Genome Project. Post Human Genome Project: "Omics". Bio-Pharmaceutical R&D. Stages of Bio-Pharmaceutical Drug Discovery and Clinical Development. Stage 1: Drug Discovery. Stage 2: Pre-Clinical Research. Stages 3–4: Clinical Trials and FDA Review. The Emerging Importance of "Biologics". Biomarkers and Stratified/Personalized Medicine. The Past and Future of Bio-Pharmaceutical R&D. Semiconductors: Progress through Collaboration. Life Sciences Industry: Exclusive IP Deals and Limited Collaboration. IMI and AMP. Nanomedicine. Computers in Nanomedicine. Biocompatible Nanoparticles and Targeted Drug Delivery. Dendrimers. Liposomes. Targeted Drug Delivery. The Business of Nanotherapeutics. Biomedical and Molecular Imaging. Nanodiagnostics. Regenerative Medicine: Stem Cells, Gene Therapy, Immunotherapy. Impact of Nanomedicine. The Gut Microbiome. Central Nervous System: Brain and Spinal Cord. Cancer and Immunology. Cardiovascular Disease. Diabetes. Infectious Disease. Tissue and Organ Transplantation. The Healthcare Ecosystem AND BIOMEDICAL RESEARCH FUNDING. It’s all about the Patient/Consumer. The Future of Funding for Basic Biomedical and Translational Research. Public Health and Global Health Economics. Global View of Healthcare Costs, Infant Mortality and Life Expectancy. US Health Statistics. Conclusions. Acknowledgments. References.
Dr. Michael Hehenberger is founder of HM NanoMed LLC, Connecticut, USA. He retired after a long career with IBM at the end of 2013. He earned a Dipl. Ing. in physics from the Technical University of Vienna, Austria, and obtained his Ph.D. and Dr. Sc. degrees in quantum chemistry from Uppsala University, Sweden, in 1975–79. He also spent two years at the University of Florida, Gainesville, USA, as visiting associate professor. In 1985, he joined IBM in Stockholm, Sweden, to initiate academic partnerships in computational biology, structural engineering, computer networks, and supercomputing. Throughout his IBM career that took him to European Headquarters in Paris, California (Almaden Research, San Jose), and New York, he has led collaborations with academic and global industrial life sciences organizations. The partnerships were based on the joint desire to extend the frontiers of computational chemistry and biology, information-based medicine, biopharmaceutical research, and nanomedicine. His efforts have been documented in over 40 publications and book chapters.
"This is an exceptional book. It is not only written very
intelligently but also most impressively in a form that brings into
play all the important aspects of modern medicine, connecting them
in a remarkably comprehensive fashion. It is an excellent book not
just about nanomedicine in particular, but about medicine in
general."
— Gerd Binnig - Nobel Laureate and Founder, Definiens,
Germany"Michael Hehenberger is a master chef, blending clear
explanations of scientific concepts with historical accounts of
discovery and commercialization efforts, accounts that are spiced
with observations on the political and economic environment in
which this is occurring, to create an informative, interesting, and
thought-provoking book. Nanomedicine: Science, Business, and Impact
will appeal to a wide range of readers, including scientists,
investors, politicians—in short, anyone interested in the impact
that emerging nanotechnologies will have on the practice of
medicine."
— Christopher K. McLeod, Angel Investor, Ex-President and CEO,
Roche 454 Life Sciences, USA "I am grateful and amazed that the
book goes beyond science and business by also covering societal,
ethical, and regulatory aspects. Dr. Hehenberger deserves
commendation for capturing the unique interdisciplinary character
of nanomedicine. I strongly recommend the book to both experts and
non-experts, who will get new and broader insights into this
field."
— Dr. Beat Löffler, CEO, European Foundation for Clinical
Nanomedicine, Switzerland"Nanomedicine by Michael Hehenberger is an
amazing book which should be read again and again: just like a
genome, (well) organized and (very) accurate, beautiful and
meaningful."
— Prof. Huanming (Henry) Yang, Chairman and Co-founder, BGI,
China"A fascinating page-turner like the latest thriller—and one of
the very few books in science and technology that cover equally
well all three aspects of progress: scientific invention, science
developed into new technology, and business as the result of
creating customer (patient) benefit. A very remarkable piece of
work that will get a preferred place in my library, because it is
easy to read, yet always solid and correct."
— Dr. Manfred Baier, Former General Manager of Roche Applied
Science, Germany"The author gives investors the tools they need to
understand science as an investment. His incisiveness into medical
technologies within a business modality makes this a fascinating
read."
— Lewis C. Pell, Medical Technology Entrepreneur and Angel
Investor, New York City, USA"Michael Hehenberger provides a
comprehensive encyclopedia of nanomedicine and its sites of
intersection with novel cutting-edge technologies, major diseases
and applications as well as with business, ethical, regulatory, and
societal aspects. I am particularly thrilled that the book covers
the connections between nanomedicine, next-generation sequencing,
and genomics, the key elements on the road to precision
(personalized) medicine."
— Prof. Jan Mollenhauer, Editor-in-Chief, European Journal of
Nanomedicine"This is an interesting attempt by the author to view
the development of nanomedicine science from a different angle and
give us the bigger picture. The book, written for non-specialists,
takes us, in some detail, through the basics of various fields of
science, which through interdisciplinary interaction form the
complex network that today is the basis of state-of-the-art
medicine. Additionally, it lets us understand how research projects
evolve in the presence of federal and private funding, and how the
business aspects interact to form a successful outcome. This
subject is of interest to the layperson, the scientist, the
businesspeople, and the politicians in order to understand the
context in which 21st-century medicine operates. If we are to be
successful in our quest to cure the diseases of modern society,
this understanding is instrumental for efficient progress.
Personally, I found it to be enjoyable reading and it taught me a
lot about aspects which I, as a scientist, normally would not
consider."
— Prof. Roland Lindh, Uppsala University, Sweden"Michael
Hehenberger has written a comprehensive and very readable
description covering the science, business, and impact of
nanotechnology’s intersection with chemistry, biology, and
healthcare. He tackles a scope that is staggering and almost beyond
the reach of any individual practitioner of these disciplines.
Therefore, the synthesis achieved in this book is remarkably lucid
and useful. Particularly unique and enjoyable is the blend of
science and business. The section on biopharmaceutical R&D is a
comprehensive walk through the traditional aspects of drug
discovery and drug development and blends insightful commentary on
business aspects. For example, the business pressures of
biopharmaceutical industry are wonderfully narrated with Sanofi as
a case study. Another in-depth and enjoyable treatment is of the
spectrum of companies in the area of regenerative medicine. To
scientists and students of these scientific disciplines this book
provides a very useful and comprehensive extension into the
business impact of their domain. To business students and business
executives, this book provides an interesting and deep connection
to the science and history that drives these industries."
— Dr. Ajay K. Royyuru, IBM Thomas J. Watson Research Center,
USA"The book describes the history, the developments, the
frontiers, and the future of nanomedicine and is highly recommended
for scientists, medical professionals, politicians, investors, drug
and medical device developers, regulatory authorities, and
bioethicists interested in translational issues in medicine."
— Prof. Gerd Schmitz, University Hospital Regensburg, Germany
"This is an exceptional book. It is not only written very
intelligently but also most impressively in a form that brings into
play all the important aspects of modern medicine, connecting them
in a remarkably comprehensive fashion. It is an excellent book not
just about nanomedicine in particular, but about medicine in
general."
— Gerd Binnig - Nobel Laureate and Founder, Definiens,
Germany"Michael Hehenberger is a master chef, blending clear
explanations of scientific concepts with historical accounts of
discovery and commercialization efforts, accounts that are spiced
with observations on the political and economic environment in
which this is occurring, to create an informative, interesting, and
thought-provoking book. Nanomedicine: Science, Business, and Impact
will appeal to a wide range of readers, including scientists,
investors, politicians—in short, anyone interested in the impact
that emerging nanotechnologies will have on the practice of
medicine."
— Christopher K. McLeod, Angel Investor, Ex-President and CEO,
Roche 454 Life Sciences, USA "I am grateful and amazed that the
book goes beyond science and business by also covering societal,
ethical, and regulatory aspects. Dr. Hehenberger deserves
commendation for capturing the unique interdisciplinary character
of nanomedicine. I strongly recommend the book to both experts and
non-experts, who will get new and broader insights into this
field."
— Dr. Beat Löffler, CEO, European Foundation for Clinical
Nanomedicine, Switzerland"Nanomedicine by Michael Hehenberger is an
amazing book which should be read again and again: just like a
genome, (well) organized and (very) accurate, beautiful and
meaningful."
— Prof. Huanming (Henry) Yang, Chairman and Co-founder, BGI,
China"A fascinating page-turner like the latest thriller—and one of
the very few books in science and technology that cover equally
well all three aspects of progress: scientific invention, science
developed into new technology, and business as the result of
creating customer (patient) benefit. A very remarkable piece of
work that will get a preferred place in my library, because it is
easy to read, yet always solid and correct."
— Dr. Manfred Baier, Former General Manager of Roche Applied
Science, Germany"The author gives investors the tools they need to
understand science as an investment. His incisiveness into medical
technologies within a business modality makes this a fascinating
read."
— Lewis C. Pell, Medical Technology Entrepreneur and Angel
Investor, New York City, USA"Michael Hehenberger provides a
comprehensive encyclopedia of nanomedicine and its sites of
intersection with novel cutting-edge technologies, major diseases
and applications as well as with business, ethical, regulatory, and
societal aspects. I am particularly thrilled that the book covers
the connections between nanomedicine, next-generation sequencing,
and genomics, the key elements on the road to precision
(personalized) medicine."
— Prof. Jan Mollenhauer, Editor-in-Chief, European Journal of
Nanomedicine"This is an interesting attempt by the author to view
the development of nanomedicine science from a different angle and
give us the bigger picture. The book, written for non-specialists,
takes us, in some detail, through the basics of various fields of
science, which through interdisciplinary interaction form the
complex network that today is the basis of state-of-the-art
medicine. Additionally, it lets us understand how research projects
evolve in the presence of federal and private funding, and how the
business aspects interact to form a successful outcome. This
subject is of interest to the layperson, the scientist, the
businesspeople, and the politicians in order to understand the
context in which 21st-century medicine operates. If we are to be
successful in our quest to cure the diseases of modern society,
this understanding is instrumental for efficient progress.
Personally, I found it to be enjoyable reading and it taught me a
lot about aspects which I, as a scientist, normally would not
consider."
— Prof. Roland Lindh, Uppsala University, Sweden"Michael
Hehenberger has written a comprehensive and very readable
description covering the science, business, and impact of
nanotechnology’s intersection with chemistry, biology, and
healthcare. He tackles a scope that is staggering and almost beyond
the reach of any individual practitioner of these disciplines.
Therefore, the synthesis achieved in this book is remarkably lucid
and useful. Particularly unique and enjoyable is the blend of
science and business. The section on biopharmaceutical R&D is a
comprehensive walk through the traditional aspects of drug
discovery and drug development and blends insightful commentary on
business aspects. For example, the business pressures of
biopharmaceutical industry are wonderfully narrated with Sanofi as
a case study. Another in-depth and enjoyable treatment is of the
spectrum of companies in the area of regenerative medicine. To
scientists and students of these scientific disciplines this book
provides a very useful and comprehensive extension into the
business impact of their domain. To business students and business
executives, this book provides an interesting and deep connection
to the science and history that drives these industries."
— Dr. Ajay K. Royyuru, IBM Thomas J. Watson Research Center,
USA"The book describes the history, the developments, the
frontiers, and the future of nanomedicine and is highly recommended
for scientists, medical professionals, politicians, investors, drug
and medical device developers, regulatory authorities, and
bioethicists interested in translational issues in medicine."
— Prof. Gerd Schmitz, University Hospital Regensburg, Germany
|
Ask a Question About this Product More... |
|
